Table 6.

Influence of different combined oral contraceptive formulations in the carbohydrate metabolism biomarkers of polycystic ovary syndrome

COC formulation	Number of studies	Before Md (1st – 3rd)	After Md (1st – 3rd)	∆	p*
Glucose (mg/dl)
EE 35 μg / CPA 2 mg	12	86.6 (81.0–92.0)	85.6 (84.3–91.9)	−1.0	0.514
EE 30 μg / DRSP 3 mg	10	84.4 (78.7–91.2)	85.7 (80.6–90.6)	+1.3	0.998
EE 30 μg / CMA 2 μg	2	86.0(84.5–87.5)	81.8 (80.5–83.1)	−4.2	0.010
EE 30 μg / DSG 75–150 μg	5	84.5 (81.3) – 88.9)	85.2 (81.9–88.0)	+0.7	0.892
Insulin (μUI/ml)
EE 35 μg / CPA 2 mg	11	17.9 (10.8–22.8)	17.1 (10.0–18.6)	−0.8	0.213
EE 30 μg / DRSP 3 mg	08	13.9 (11.3–18.1)	12.1 (10.1–18.5)	−1.8	0.865
EE 30 μg / CMA 2 mg	03	7.3 (5.2–9.4)	7.8 (6.1–9.5)	+0.5	0.285
EE 30 μg / DSG 75–150 μg	04	15.7 (13.0–19.0)	17.1 (13.1–22.1)	+1.4	0.144
EE 30 μg / 180–250 μg NGM	02	8.9 (7.6–10.2)	9.1(7.2–11.0)	+0.2	0.788
C-peptide (mg/dl)
EE 35 μg / CPA 2 mg	03	2.6 (2.0–3.2)	3.0 (2.9–3.9)	+0.4	0.179
EE 30 μg / DRSP 3 mg	03	1.2 (0.7–1.7)	1.3 (0.7–1.9)	+0.1	0.654
EE 30 μg / DSG 75–150 μg	02	1.6 (1.5–1.7)	2.4 (2.0–2.8)	+0.8	0.179
HOMA-IR
EE 35 μg / CPA 2 mg	09	3.6 (2.0–4.4)	2.2 (1.8–3.9)	−1.4	0.213
EE 30 μg / DRSP 3 mg	10	3.1 (2.2–3.7)	2.8 (2.5–3.8)	−0.3	0.593
EE 30 μg / CMA 2 mg	03	1.6 (1.2–2.0)	1.6 (1.3–2.0)	0	0.592
EE 30 μg / DSG 75–150 μg	03	3.0 (2.3–3.7)	2.6 (2.2–3.0)	−0.4	0.285
HbA1C (%)
EE 35 μg / CPA 2 mg	04	5.0 (4.6–5.4)	5.1 (4.7–5.6)	+0.1	0.422
EE 30 μg / DRSP 3 mg	02	3.5 (2.7–4.3)	3.5 (1.7–7.3)	0	0.653

COC combined oral contraceptive, Md (1st – 3rd) median, first and third quartiles, HOMA-IR homeostatic model assessment for insulin resistance, HbA1C glycated hemoglobin, EE ethinylestradiol, CPA cyproterone acetate, DRSP drospirenone, CMA chlormadinone acetate, DSG desogestrel, NGM norgestimate

p* Wilcoxon signed- ranks test